Efficacy and safety evaluation of rasagiline in the treatment of advanced Parkinson's disease

Rasagiline (Rasagiline) is a selective monoamine oxidaseB inhibitor (MAO-B inhibitor). It is widely used in the treatment of Parkinson’s disease (Parkinson’s Disease, PD), especially in the comprehensive management of advanced patients. This article will evaluate in detail the efficacy and safety of rasagiline in the treatment of advanced Parkinson's disease, with a view to providing a reference for clinical medication.

1. Mechanism of action and indications of rasagiline

Rasagiline selectively and irreversibly inhibits monoamine oxidaseB (MAO-B) in the brain, reducing the metabolic degradation of dopamine and increasing dopamine levels in the brain, thereby improving motor symptoms. It may also have neuroprotective effects, slowing down neuronal damage through antioxidant and anti-apoptotic mechanisms. Rasagiline is mainly used to treat the "on--off" fluctuations of early-stage monotherapy and late-stage combination treatment with levodopa in Parkinson's disease. It can effectively improve motor function and quality of life.

2. The efficacy of rasagiline in the treatment of advanced Parkinson's disease

Patients with advanced Parkinson's disease usually have significant motor fluctuations and motor complications, such as"on-off" phenomenon, bradykinesia and drug-induced dyskinesia. Multiple clinical studies have shown that rasagiline, as an auxiliary treatment drug, can significantly extend patients' daily "on" state time, reduce "off" state time, and improve motor function.

For example, TEMPO and LARGO are two key III clinical trials Trials have shown that rasagiline-adjuvanted levodopa treatment can reduce daily "off" status by approximately 1 hours while improving motor scores (UPDRS) and patient self-evaluation. Especially in advanced patients, the sustained effect of rasagiline can reduce movement fluctuations and improve mobility. In addition, rasagiline also has a certain effect on non-motor symptoms such as fatigue and mood disorders, thereby improving the overall quality of life.

3. Safety Assessment

Rasagiline is generally well tolerated. Common adverse reactions include headache, arthralgia, insomnia and gastrointestinal discomfort, which are usually mild to moderate. Late-stage patients may have multiple diseases and multiple drug treatments, so they need to pay attention to drug interactions and the risk of superimposed side effects.

Rasagiline and othersMAODifferent inhibitors have less impact on tyramine in the diet, and the risk of hypertensive crisis is low, but it is still necessary to avoid combining it with certain antidepressants, sedatives, etc. to prevent serious adverse events. Some patients may experience psychiatric symptoms such as hallucinations and anxiety, especially elderly and terminally ill patients, and should be closely monitored and the dosage adjusted.

4. Precautions for clinical use

Patients with advanced Parkinson's disease have large individual differences, and treatment plans need to be individualized. The dosage of rasagiline is usually 1 mg orally daily and should be titrated gradually when starting treatment. While patients are taking the medicine, the efficacy and adverse reactions should be regularly evaluated and the plan should be adjusted in a timely manner. It should be used with caution in patients with hepatic insufficiency as drug metabolism may be affected.

In addition, combination medication is the norm in the treatment of advanced Parkinson's disease. Rasagiline is often used in combination with levodopa, COMT inhibitors, dopamine receptor agonists, etc. to synergistically improve motor symptoms, but it also increases the complexity of drug interactions and requires comprehensive management by professional doctors.

5. Future Outlook

As Parkinson's disease treatment concepts advance, rasagiline's position in the management of advanced disease is increasingly consolidated. Future research may focus on the long-term effects of its neuroprotective effect and its combined application with new treatments such as cell therapy and gene therapy. In addition, optimizing medication regimens, reducing adverse reactions, and improving patient compliance are also the direction of future efforts.

As a selective MAO-B inhibitor, rasagiline has a significant effect on improving motor symptoms in patients with advanced Parkinson's disease. It can especially effectively prolong the "on" state, reduce the "off" state, and improve the patient's quality of life. It has a good safety profile and common side effects are mild and controllable, but attention needs to be paid to the special medication risks in elderly patients. Individualized treatment and multidisciplinary collaboration are key to ensuring successful treatment. In short, rasagiline is an important drug in the comprehensive treatment of advanced Parkinson's disease and is expected to be combined with more emerging therapies in the future to provide patients with more comprehensive treatment options.

Reference materials:https://www.drugs.com/